Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Mar 24, 2025--
Aditxt, Inc. (NASDAQ: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ('Pearsanta'), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.
Pearsanta acquired the patents in exchange for the issuance of Pearsanta Convertible Preferred Stock in a transaction valued at approximately $1 million. Over the next two to three years, Pearsanta will seek to advance clinical validation, regulatory submissions, and commercialization efforts to integrate this technology into its diagnostic portfolio.
The acquisition aligns with Pearsanta's mission to advance early cancer detection and prevention that is globally accessible. Mitomic ® Technology, Pearsanta's proprietary platform, uses mitochondrial DNA biomarkers designed for non-invasive cancer detection. With the addition of adductomics-based DNA damage analysis, Pearsanta is expanding its capabilities to assess carcinogen exposure and genomic instability before permanent mutations occur, reinforcing its commitment to proactive cancer risk assessment.
Enhancing Early Cancer Detection with Adductomics
The acquired patents cover proprietary advancements in DNA adduct detection and analysis, providing the capability to assess genomic instability caused by environmental toxins and metabolic byproducts. DNA adducts—chemical modifications to DNA nucleotides caused by carcinogens—are among the earliest detectable indicators of cancer risk.
Pearsanta intends to develop this platform into a comprehensive, panoramic assessment tool for DNA adducts, utilizing urine, blood or solid tissue samples to provide actionable insights into DNA damage before mutations occur. This approach has the potential to identify environmental or biological factors contributing to cancer risk, offering earlier intervention strategies for individuals at elevated risk.
Advancing Toward Commercialization
Pearsanta is advancing a strategic development plan to bring adductomics-based diagnostics to market, focusing on:
Clinical validation to confirm the technology's effectiveness in assessing cancer risk.
Regulatory submissions to support integration into Laboratory Developed Tests (LDTs) and future FDA pathways.
Scalability within CLIA/CAP-certified laboratories, seeking to ensure clinical access and, ultimately, commercial adoption.
Over the next two to three years, Pearsanta aims to incorporate adductomics-based screening into its expanding portfolio of precision oncology solutions, reinforcing its commitment to shifting cancer diagnostics from late-stage detection to proactive prevention.
Pearsanta's Role in the Future of Cancer Prevention
Current cancer diagnostics predominantly detect tumors after they have developed, leaving patients with limited treatment options that are often costly and less effective. Pearsanta's approach, strengthened by the acquisition of adductomics technology, represents a new frontier in cancer prevention, potentially facilitating identification of DNA damage at its earliest molecular stages—before irreversible mutations occur.
'We envision a world where cancer risk can be assessed before symptoms appear, giving patients and physicians the opportunity to intervene when it matters most,' said Chris Mitton, President of Pearsanta. 'We believe that Pearsanta is uniquely positioned to shift cancer care from reactive treatment to proactive prevention. This advancement has the potential to redefine cancer care by enabling earlier risk assessment, allowing individuals to adjust lifestyle factors, reduce exposure to carcinogens and adopt personalized prevention strategies. In underserved regions, where access to oncology treatments remains limited, we believe that adductomics-based screening could provide a cost-effective tool for early cancer risk assessment, empowering preventive measures when they are most effective.'
Additionally, by detecting DNA damage before disease progression, this technology has the potential to lower the overall economic burden of cancer, reducing the reliance on late-stage treatments and hospitalizations.
'Pearsanta's acquisition reflects Aditxt's commitment to driving innovation with the potential of addressing some of the most pressing health challenges such as cancer,' said Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt. 'We believe that this technology has the potential to redefine how we assess and mitigate cancer risk, which could reshape the future of early detection and prevention of cancer.'
About Pearsanta
Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid biopsy tests. Pearsanta's asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit www.pearsanta.com.
About Aditxt
Aditxt, Inc. ® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to 'Make Promising Innovations Possible Together.' The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress.
Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women's health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. ('Appili') (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. ('Evofem') (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt's mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. On Dec. 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements' within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's ability to finance and execute its strategic M&A initiatives; the Company's ability to obtain the necessary funding and partner to commence clinical trials; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company's ability to raise additional capital; expected usage of the Company's ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled 'Risk Factors' in Aditxt's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Corporate Communications
Jeff Ramson, PCG Advisory, Inc.
T: 646-863-6893
SOURCE: Aditxt, Inc.
Copyright Business Wire 2025.
PUB: 03/24/2025 08:15 AM/DISC: 03/24/2025 08:15 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
1 Soaring Growth Stock to Buy Hand Over Fist Before It Is Too Late
Applied Materials stock is in rebound mode. Even better, it still trades at an attractive valuation. The semiconductor equipment supplier expects stronger growth in the future due to increased spending by chipmakers and foundries. Applied Materials stock could deliver terrific gains going forward thanks to favorable end-market developments. 10 stocks we like better than Applied Materials › Share prices of Applied Materials (NASDAQ: AMAT) have jumped impressively from the 52-week lows they hit just over two months ago, gaining 31% in a short time on the back of the broader rally in the tech-laden Nasdaq Composite index that has clocked solid gains of 25% during the same period. What's worth noting is that investors shrugged off Applied Materials' mixed fiscal 2025 second-quarter results (for the three months ended April 27), which were released on May 15. The semiconductor equipment supplier reported robust growth in sales and earnings for the quarter, but its top line was a tad lighter than expected. The company's outlook for the current quarter followed a similar pattern. However, savvy investors would do well to note that Applied Materials' results and guidance were resilient at a time when the tariff-fueled turmoil and the restrictions on sales of semiconductor equipment to China are turning out to be headwinds for the company. Let's take a look at the factors that could help Applied Materials stock maintain its momentum on the market. Applied Materials reported year-over-year growth of 7% in its revenue in the previous quarter, while its non-GAAP earnings per share (EPS) increased at a faster pace of 14%. A quarter of its revenue came from sales of semiconductor manufacturing equipment to China. For comparison, Applied Materials' top-line growth was flat in the same quarter last year, while its adjusted earnings increased at a much slower pace of 5%. Applied Materials got 43% of its revenue from Chinese customers in the year-ago period. So, the company's growth accelerated even though restrictions on sales of advanced chipmaking equipment to Chinese customers hurt its business in its largest market abroad. This can be attributed to the global growth in semiconductor demand owing to catalysts such as artificial intelligence (AI). Equity research firm Summit Insights Group predicts that the improvement in demand for advanced chips in the second half of 2025 and next year should allow Applied Materials to continue doing well even if its Chinese business remains negatively impacted. Applied Materials CEO Gary Dickerson's remarks on last month's earnings conference call suggest something similar: The impact of AI datacenter innovation and investments is apparent in the wafer fab equipment market, where there are significant shifts in the spending mix this year. We see investment in leading edge foundry-logic growing substantially in 2025, and we also expect spending for leading-edge DRAM to be up significantly. Large-scale AI infrastructure investments such as the $500 billion Stargate project and the multibillion-dollar investments by cloud-computing giants to bolster their AI capabilities are the reasons why foundries and chipmakers are focused on enhancing their manufacturing capacities. Foundry giant Taiwan Semiconductor Manufacturing (NYSE: TSM), for instance, is set to increase its capital expenditures (capex) by 38% at the midpoint of its forecast to $40 billion in 2025. The Taiwan-based company is on track to build nine fabrication plants this year. TSMC further points out that it will spend 70% of its capital spending on advanced process nodes. That's not surprising as almost three-fourths of the company's revenue comes from selling chips manufactured using advanced nodes that are 7-nanometer (nm) or smaller in size. Looking ahead, TSMC estimates that its revenue from sales of AI chips is likely to increase at an annual rate of mid-40% through 2029. So, it won't be surprising to see the company spending more money on shoring up the production capacity of advanced chips to meet the AI-fueled demand. The increase in capex by the likes of TSMC is expected to drive a 2% increase in global semiconductor equipment spending this year to $110 billion, followed by a much stronger increase of 18% in 2026. This should ideally lead to an acceleration in Applied Materials' growth as well, paving the way for more stock price upside. Analysts are forecasting a 10% increase in Applied Materials' earnings this fiscal year to $9.49 per share. This is expected to be followed by a smaller jump in fiscal 2026 before another year of double-digit growth in fiscal 2027. However, the sharp acceleration in global semiconductor equipment spending could allow Applied Materials to grow at a faster rate over the next couple of years. But even if the company's bottom line grows in line with consensus expectations and its earnings hit $11.17 per share after a couple of fiscal years (as per the chart above), its stock price could jump to $329 (based on the tech-laden Nasdaq-100 index's forward earnings multiple of 29). That points toward an 88% gain from current levels in the next three years. Applied Materials stock is now trading at just 18 times forward earnings, which is a nice discount to the Nasdaq-100 index, which serves as a proxy for tech stocks. However, the market could reward Applied Materials with a richer earnings multiple in the future if it can deliver stronger-than-expected earnings growth. That's why savvy investors may want to buy this semiconductor stock while it is still trading at an incredibly cheap valuation, as it has the ability to go on a terrific bull run going forward. Before you buy stock in Applied Materials, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Materials wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Applied Materials and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. 1 Soaring Growth Stock to Buy Hand Over Fist Before It Is Too Late was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Wells Fargo Lifts PT on Intuit (INTU) Stock, Keeps Overweight
Intuit Inc. (NASDAQ:INTU) is one of the 10 software stocks analysts are upgrading. On June 13, Wells Fargo analyst Michael Turrin upped the company's price objective to $880 from $825, while keeping an 'Overweight' rating, as reported by The Fly. The firm believes that reduced economic uncertainties and a resurgence in typical purchasing patterns are expected to result in a recovery in the broader software sector during the latter part of the year. Intuit Inc. (NASDAQ:INTU) delivered a healthy Q3 2025 thanks to the outstanding tax season and continued momentum in its Global Business Solutions Group and Credit Karma. A professional tax preparer, using a laptop to complete an income tax return. During Q3 2025, Intuit Inc. (NASDAQ:INTU)'s Global Business Solutions Group revenue rose to $2.8 billion, reflecting a rise of 19%. Furthermore, the Online Ecosystem revenue increased to $2.1 billion, up by 20%. For the full fiscal year, Intuit Inc. (NASDAQ:INTU) expects TurboTax Live revenue to increase by 47% to $2.0 billion, representing ~40% of total Consumer Group revenue, while TurboTax Live units are expected to grow by 24%. TurboTax Online paying units are expected to grow ~6% due to share gains from higher average revenue per return (ARPR) filers, with ARPR likely to increase ~13% as more customers choose assisted offerings and faster access to refunds. Parnassus Investments, an investment management company, released the Q3 2024 investor letter. Here is what the fund said: 'Intuit Inc. (NASDAQ:INTU) shares fell despite the financial software company posting strong quarterly results. The company's pricing-dependent long-term guidance concerned investors. However, we continue to believe Intuit's customer growth and relevant platform will sustain its wide moat and long growth runway.' Intuit Inc. (NASDAQ:INTU) is a leading player in the broader software industry, as it is known for its financial and tax software products. While we acknowledge the potential of INTU to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INTU and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
35 minutes ago
- Yahoo
Wells Fargo Upgrades Zscaler (ZS) Stock, Lifts PT
Zscaler, Inc. (NASDAQ:ZS) is one of the 10 software stocks analysts are upgrading. On June 13, Wells Fargo upgraded the company's stock to 'Overweight' from 'Equal Weight,' lifting the price objective to $385 from the previous target of $260. As per the firm, software infrastructure spending in H2 2025 is expected to be driven by the adoption of agentic AI, which tends to benefit several software companies, including Zscaler, Inc. (NASDAQ:ZS). An employee standing in front of a large data center, looking toward the future of cloud security. The research firm cited Zscaler, Inc. (NASDAQ:ZS)'s potential to reach $5 billion in annual recurring revenue by fiscal 2027 as one of the measures of the upgrade. Despite the increase in the stock price YTD, the firm believes it still possesses significant room for multiple expansion. Well Fargo expects more than 20% billings growth in FY 2026 and continues to see margin expansion continuing, together with revenue growth. Notably, the company's stock has increased by ~66% on a YTD basis. In May 2025, Zscaler, Inc. (NASDAQ:ZS) signed a definitive agreement to acquire Red Canary, which is a leading managed detection and response (MDR) vendor. Through the combination of Zscaler, Inc. (NASDAQ:ZS)'s high-volume and high-quality data with Red Canary's domain expertise in MDR, Zscaler, Inc. (NASDAQ:ZS) plans to ramp up its vision to deliver AI-powered security operations. While we acknowledge the potential of ZS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Sign in to access your portfolio
